What are direct-acting oral anticoagulants (DOACs)?
Dabigatran is a direct-acting oral anticoagulants (DOACs) which are medicines used to prevent and treat blood clots.
This medicine interferes with normal blood clotting (coagulation). It is commonly known as a “blood thinner” although it does not actually cause the blood to become less thick, only less likely to clot. It helps to reduce the risk of blood clot formation or to treat blood clots that have already formed. Dabigatran does not dissolve clots that have already been formed but may prevent the clots from growing larger, while letting the body’s natural processes dissolve the clots.
People who are taking this medicine do not require frequent blood tests to check the effectiveness of the medicine. Your doctor may however order blood tests to check how well your kidneys and liver are working. If you have a severe kidney or liver problem, Dabigatran may not be the right medicine for you.
□ Stroke prevention in atrial fibrillation (Irregular heart rhythm)
□Prevention of blood clot formation following hip or knee replacement surgery
□ Treatment of deep vein thrombosis (blood clot in the leg) or prevention of recurrence
□ Treatment of pulmonary embolism (blood clot which has travelled to the lung) or prevention of recurrence
□ Other Indication: __________________________________
Duration of treatment may vary from 3 to 6 months to long term depending on your condition.
The possible side effects of Dabigatran include allergic reaction, headache/dizziness or gastrointestinal discomfort (stomach irritation, gastric like symptoms). The other common side effect of Dabigatran is bleeding which is related mainly to Dabigatran’s effect of delaying blood clotting.
Check with your doctor if you experience the following side effects:
Serious effects of Dabigatran include:
Dabigatran should be taken as prescribed by the doctor, administered once or twice daily. It can be taken with or without food.
When should I take Dabigatran?
Please call the Pharmacy at ________________________ should you have any query.
Subscribe to our mailing list to get the updates to your inbox